CSS
VERV

Cubist Systematic Strategies’s Verve Therapeutics VERV Stock Holding History

Cubist Systematic Strategies’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-91,330
Closed -$417K – 3554
2025
Q1 		$417K Sell
91,330
-26,270
-22% -$176K ﹤0.01% 2241
2024
Q4 		$663K Sell
117,600
-561,025
-83% -$3.16M ﹤0.01% 2041
2024
Q3 		$3.28M Buy
678,625
+282,926
+72% +$1.64M 0.02% 1111
2024
Q2 		$1.93M Buy
395,699
+281,173
+246% +$1.77M 0.01% 1362
2024
Q1 		$1.52M Sell
114,526
-29,407
-20% -$390K 0.01% 1851
2023
Q4 		$2.01M Buy
143,933
+27,235
+23% +$338K 0.01% 1508
2023
Q3 		$1.55M Buy
116,698
+78,141
+203% +$1.26M 0.01% 1556
2023
Q2 		$723K Sell
38,557
-129,569
-77% -$2.16M ﹤0.01% 2167
2023
Q1 		$2.42M Buy
168,126
+111,004
+194% +$2.17M 0.01% 1522
2022
Q4 		$1.11M Buy
57,122
+36,936
+183% +$979K 0.01% 2354
2022
Q3 		$693K Sell
20,186
-105,943
-84% -$3.38M ﹤0.01% 2913
2022
Q2 		$1.93M Buy
126,129
+101,663
+416% +$1.57M 0.01% 1903
2022
Q1 		$558K Buy
+24,466
New +$699K ﹤0.01% 2468
2021
Q4 		– Sell
-6,406
Closed -$301K – 3652
2021
Q3 		$301K Buy
6,406
+6,055
+1,725% +$356K ﹤0.01% 2351
2021
Q2 		$21K Buy
+351
New +$14.6K ﹤0.01% 2845

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cubist Systematic Strategies's VERV Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 91,330 shares — an estimated $417K sold.

Cubist Systematic Strategies first reported a position in VERV in Q2 2021 and held it in 15 quarters. The position peaked at $3.28M in Q3 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 91,330 Verve Therapeutics shares in Q2 2025, an estimated $417K.
  • Cubist Systematic Strategies first reported a position in Verve Therapeutics in Q2 2021 and held it in 15 quarters.
  • Cubist Systematic Strategies's Verve Therapeutics position peaked at $3.28M in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.